KMT2A and Splenomegaly: At 10 months post transplantation, 2 and 3 of 5 mice transplanted with Kmt2a-PTD-BM cells expressing DNMT3A-R882C and DNMT3A-R882H/S mutants, respectively, died with marked splenomegaly and hepatomegaly compared with Kmt2a-PTD/EV-transplanted mice (Fig. 7a−c).